New weapon in liver cancer fight: targeted immune therapy before surgery
NCT ID NCT07172282
Summary
This early-stage study is testing a new approach for people with colorectal cancer that has spread to the liver. Researchers want to see if a drug called Nelitolimod, delivered directly to the liver through a special catheter, is safe and feasible to use before surgery. The goal is to see if this method can help the patient's own immune system fight the cancer in the liver, potentially improving outcomes after the tumor is removed.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER METASTATIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
RJ Zuckerberg
RECRUITINGLake Success, New York, 11042, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.